Background: This study was conducted in order to evaluate the significance of circulating free DNA (CFDNA), blood plasma p53 antibodies (p53-Ab) and mutations of KRAS gene in the prognosis of ovarian epithelial cancers.
introduction
Epithelial ovarian cancer comprises the majority of malignant ovarian tumors in adult women. About 190 000 new cases and 114 000 deaths from ovarian cancer are estimated to occur annually. The highest rates are reported in Scandinavia and Eastern Europe, the United States and Canada. The age-adjusted incidence rate in the United States is 12.48 per 100 000 women per year [1] . Low rates are found in Africa and Asia [2] . In Poland, the age-adjusted incidence is 10.8 per 100 000 women per year [3] . The overall 5-year survival rate for all stages combined range from 30% / INS> to 50%. Most women, however, present with late-stage disease, which is associated with a rate of about 20% [4] .
Activation of protooncogenes is a feature of many malignancies and, not surprisingly, there have been numerous searches for oncogene mutations as well as for specific genes dysregulation involved in apoptotic, neoangiogenetic and transduction signal pathways [5] . In ovarian cancer, KRAS mutations are seen in 4%-30% of cases [6] [7] [8] [9] [10] . TP53 mutations have been found in 50% of cases [11] [12] [13] . The frequencies of p53 antibodies (p53-Ab) in serum vary from 8% to 46% [14] [15] [16] [17] . Several methods have been used for circulating free DNA (CFDNA) quantification, but none have been evaluated in terms of reproducibility and therefore, results from different studies are not comparable [18] [19] [20] [21] [22] .
This study was conducted in order to evaluate the significance of CFDNA, blood plasma p53-Ab and mutations of KRAS gene in the prognosis of ovarian epithelial cancers. 
materials and methods patient and clinical samples

KRAS mutation detection
Tissue specimens of ovarian cancer were obtained during surgery and immediately frozen in liquid nitrogen and then stored at a temperature of 280°C until analyzed. Before DNA extraction, it was microscopically confirmed that the tumor specimens consisted mainly of carcinoma tissue (80%). Tumor samples (30-50 mg) were minced with a sterile scalpel and then digested overnight in 180 ll of tissue lysis buffer, containing 20 ll of proteinase K solution (10 mg/ml) at 37°C. DNA extraction from tissue lysates was carried out with the GeneElute Mammalian Genomic DNA Miniprep Kit (SigmaAldrich, St Louis, MO), according to the manufacture's instructions. Isolated DNA was stored at a temperature of 220°C before further assays.
The detection of KRAS mutations at codon 12 was carried out using PCR-restriction fragment length polymorphism (PCR-RFLP) method as described previously [7, 23] . PCR products were sequenced with the use of the sense primer K1, the ABI PRISM BigDye Terminator v3.0 Cycle Sequencing Ready Reaction (Applied Biosystems, Foster City, CA) and the automated ABI PRISM 377 DNA sequencer (Applied Biosystems). Mutations were confirmed by sequencing reaction with the use of the antisense primer DD5P. Antisense strain of PCR products was used for sequencing.
circulating free DNA Three-milliliter sample of peripheral blood was collected in vials containing EDTA on the day before surgery. Plasma was immediately separated from the cellular fraction by centrifugation at 3000 g for 20 min at 4°C and then stored at 280°C. DNA isolation from 200 ll blood plasma was carried out with commercial kit for blood DNA isolation of Sigma-Aldrich according to manufacturer's specifications. DNA solutions were stored at a temperature of 280°C before mutation detection. KRAS codon 12 mutation was detected by enriched PCR-RFLP method with some modification [23] . The method consists of two DNA amplification and two digestion reactions.
assay of p53-Ab in plasma
A three-milliliter sample of peripheral blood was collected in vials containing EDTA on the day before surgery. Plasma was immediately separated from the cellular fraction by centrifugation at 3000 g during the period of 20 min at a temperature of 4°C and the supernatant was stored at a temperature of 280°C until use.
The level of p53-Ab in plasma was measured with the use of anti-p53 ELISA II Kit (Pharmacell, Paris, France) according to the manufacture's instruction. The value over 0.85 IU/ml indicates a probable presence of the antibody.
statistical analysis
Statistical analysis was carried out using Statistica software version 8.0 (StatSoft Inc., StatSoft Polska Sp. z o.o., Poland). A chi-square test was used to evaluate the relationship between categorical variables. Fisher's exact test was used to determine significance between the two groups. A P value of <0.05 was considered as statistically significant. In addition, survival time was calculated from the date of surgery to the date of death and survival analysis was carried out using the Kaplan-Meier method.
results
KRAS gene mutations
Our results show that mutations of the KRAS gene in codon 12 were present in 27 of 126 cases (21.4%) examined with epithelial ovarian cancer ( Figure 1 ). We found this frequency to be lower in serous tumors (12.5%), with a slight increase to 23.1% in endometrioid tumors and an increase to 61.1% in mucinous carcinomas. These differences were statistically significant (P < 0.001) ( Table 1) . KRAS mutations were present in all analyzed types of the ovarian tumors, the most commonly, in grade 1 of histopathological differentiation. These differences are not statistically significant (Table 2) .
Among patients with KRAS-mutated mucinous cystadenocarcinomas, the Kaplan-Meier survival estimates of the 1-year and 5-year survival rates were 97.4% and 90.8%, respectively, while the respective rates among patients with lack of KRAS mutations were 97.4% and 93.4%. Statistically significant difference was observed between survival rates over time (P = 0.03) (Figure 2 ). Presence of KRAS gene mutation was not associated with survival outcome in serous and endometrioid tumors (data not shown).
circulating free DNA CFDNA was detectable in 55 of treated patients (43.7%). Among them, there were 39 patients with serous tumors (60.9%), 2 patients with mucinous tumors (11.1%) and 8 with endometrioid tumors (30.8%). The difference between the groups was statistically significant (P < 0.001). A positive correlation was found between the presence of CFDNA and the grade (mostly in G2 and G3; P < 0.001) at late tumor stage (III/IV; P < 0.001) and only in serous cancers (Tables 2 and 3 and Figure 3 ).
The Kaplan-Meier survival estimates of the 1-year and 5-year survival rates for patients with serous cystadenocarcinomas and the presence of CFDNA were original article Annals of Oncology 97.4% and 90.8%, respectively, while the respective rates for patients with absence of CFDNA were 97.4% and 93.4%. The median overall survival was 21 months for patient with CFDNA presence and 52 months for patient with CFDNA absence. The differences were statistically significant (P = 0.022) (Figure 4 ). The survival rate was unaffected by presence of CFDNA in mucinous and endometrioid tumors (data not shown).
positivity of plasma p53-Ab
Using the cutoff value, 42 (33.3%) of 126 patients were p53-Ab positive. The increased presence of Ab to p53 in plasma of women with serous ovarian cancer (57.8%) was statistically significant as compared with other examined ovarian cancer (P < 0.001) ( Table 1) . Plasma of women with advanced stage (III/IV) of serous ovarian cancer was more likely to have detectable antibodies specific for p53 (96.4%) than samples taken from patients with early-stage (I/II) disease (27.8%) (P < 0.001) ( Table 3 ). There was a tendency toward a higher presence of Ab to p53 in plasma of the serous cystadenocarcinomas than remaining histological subtypes of epithelial ovarian cancer. The p53-Ab was especially high in the G2 and G3 serous ovarian cancer (81.8% and 100%, respectively) (P < 0.001) ( Table 2 ). The Kaplan-Meier survival estimates of the 1-year and 5-year survival rates in p53-Ab-positive patients with serous cystadenocarcinomas were 86.4% and 72.7%, respectively, while the respective rates among p53-Ab-negative patients were 100% and 84.8%. The median overall survival was 11 months for p53-Ab-positive patient and 57 months for p53-Ab-negative patient. The differences were statistically significant (P < 0.001) ( Figure 5 ). Presence of p53-Ab in plasma of patients with mucinous and endometrioid tumors did not influence survival significantly (data not shown). original article
Annals of Oncology discussion
Recently, a dualistic model of ovarian serous carcinogenesis has been proposed [24] [25] [26] . In this model, ovarian cancers are divided into two types. Type I tumors include low-grade serous, mucinous, endometrioid and clear-cell carcinomas and malignant Brenner tumors. These are characterized by a high frequency of mutations of KRAS, low proliferation and a 5-year survival of 55% [27] [28] [29] . Type II tumors are composed of what are currently classified as moderately and poorly differentiated serous carcinoma, malignant mixed mesodermal tumors and undifferentiated carcinoma. They are characterized by a high frequency of mutations in TP53 and a high proliferative index [29, 30] . Type I tumors evolve slowly and are associated with distinct molecular changes that are rarely found in type II tumors. In contrast, type II tumors grow up rapidly, arising directly from the surface epithelium or inclusion cysts and metastasize early in their course [8, 27, 31] . Thus, there is a need to discover novel biomarkers for early diagnosis and prediction of prognosis.
The unexpected high frequency of KRAS mutations in type I tumors supports the hypothesis that KRAS mutations are genetic events closely related to the development of a mucinous phenotype in ovarian cancer [10, 28, 32] . As it is shown in Table 4 , KRAS mutations are quite frequent in ovarian mucinous tumors when compared with other histological types. However, the lack of a statistically significant correlation between KRAS mutations and stage or grade in our study indicates that we cannot rely on this molecular genetic abnormality for the identification of cancer patients for whom more aggressive treatment is necessary.
Serum p53-Ab is predominantly associated with P53 gene missense mutations and P53 accumulation in the tumor. They have been found in human cancer patients with a specificity of 96%, but the sensitivity of such detection is only 30% [16] . In our study, plasma p53-Ab was detected in 33.3% patients, which is similar to the previous findings presented in Table 4 [33] [34] [35] [36] [37] . The clinical value of these antibodies remains a subject to debate, but consistent results have been observed in other cancers in which they have been associated with high-grade tumors and poor survival [15, 23, 38] .
Point mutations in KRAS oncogene have been detected in the plasma DNA of patients with colorectal and pancreatic cancer, even preceding clinical diagnosis of pancreatic cancer by 5-14 months before clinical diagnosis [39, 40] . We also detected the same KRAS point mutation in the plasma DNA of patients with epithelial ovarian cancer. The fact that early-stage tumors of low-grade or in situ carcinomas could present DNA alterations in the plasma/serum/ascites suggests that CFDNA may become a useful diagnostic tool for early and potentially curable cancers [41] [42] [43] .
Our study showed a significant difference between the presence of CFDNA in patients with serous cancers in high grade compared with other histological subtypes. This result is in accordance with the finding of Kamat et al. [18, 21] , who reported an increase in the median levels of CFDNA in serum patients with high-grade advanced stage (III or IV) serous ovarian cancer.
Mechanisms regulating appearance and distribution of CFDNA in blood are under pressure of factors that influence its circulation and clearance including hydrolyzing enzymes. The invading cells have the ability of shedding DNA into the circulation and this may explain the high level of CFDNA in the plasma of patients with cancer [43] . Thus, elevated levels of CFDNA before diagnosis may be a promising independent DNA-based prognostic plasma marker for epithelial ovarian cancer. However, at the moment, the true origin of CFDNA is not fully understood.
In early stage of ovarian cancer, the relapse rate ranges between 10% and 40%. More than 50% of patients with advanced disease will eventually progress. Only 10%-30% of such patients attain long-term survival with a median progression-free survival of 16 months [1] [2] [3] 44] . In our study, the presence in plasma CFDNA and p53-Ab in patients with serous cystadenocarcinoma was correlated with the highest risk of cancer progression and short survival time. In mucinous cystadenocarcinomas, mutation of the KRAS gene in codon 12 may predict improved overall survival.
The results of our study suggest that the detection of KRAS mutation, CFDNA and p53-Ab in plasma of patients with type I ovarian tumors offers a possibility to individualize treatment regimen. These findings suggest that a biologically less aggressive tumor may be more amenable to optimal cytoreduction. Probably, tumor biology and other mechanisms may also influence patient's outcome. It is believed that a combined measurement of currently used tumor biomarkers will improve the sensitivity and specificity for ovarian cancer management. However, the values of longitudinal measurements of the used markers are yet to be determined. references
